GLP-1 drug could offset metabolic risks of second-generation antipsychotics ...

People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

In the early November announcement of its agreement with the government, Lilly pledged to reduce the self-pay price of ...

Ozempic (semaglutide) is a powerful and versatile drug, offering dual benefits: controlling blood sugar in type 2 diabetes, and facilitating weight loss as a secondary effect. While its primary ...

Eli Lilly reduced Zepbound vial prices for self-paying patients via LillyDirect, aiming to lower obesity treatment costs and ...

The maker of the weight loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of the blockbuster ...

Constipation is a common but manageable side effect of Ozempic, a medication for diabetes and weight loss. It often occurs in ...

Novo Nordisk offers Wegovy and Ozempic at $199/month for new self-pay patients, valid for the first two months until March 31, 2026. The promotion aligns with a national agreement to improve access ...

Eli Lilly and Novo Nordisk have announced they are working on new oral drugs that can be used for type-2 diabetes and weight loss.

The manufacturers of Ozempic and Mounjaro are creating oral weight loss medications that could change treatment methods.

Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's ...